Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2976
Summit State Bank
SSBI
$87.4M
| $224K | ﹤0.01% |
18,975
-2,640
| -12% | -$31.1K |
|
|
MTEM
2977
DELISTED
Molecular Templates, Inc.
MTEM
| $224K | ﹤0.01% |
3,450
+152
| +5% | +$12K |
|
2978
Key Tronic
KTCC
$42.8M
| $222K | ﹤0.01% |
31,300
-14,300
| -31% | -$100K |
|
|
BWP
2979
DELISTED
Boardwalk Pipeline Partners
BWP
| $220K | ﹤0.01% |
+12,200
| New | +$220K |
|
2980
Gray Media Inc
GTN.A
$612M
| $219K | ﹤0.01% |
18,700
| – | – |
|
|
RDHL
2981
Redhill Biopharma
RDHL
$3.62M
| $216K | ﹤0.01% |
25
-37
| -60% | -$356K |
|
2982
American Realty Investors
ARL
$246M
| $215K | ﹤0.01% |
25,200
+600
| +2% | +$5K |
|
|
BGFV
2983
DELISTED
Big 5 Sporting Goods
BGFV
| $215K | ﹤0.01% |
16,493
-464,900
| -97% | -$6.67M |
|
|
PVBC
2984
DELISTED
Provident Bancorp
PVBC
| $215K | ﹤0.01% |
19,278
-5,378
| -22% | -$56.5K |
|
|
ABAC
2985
DELISTED
Renmin Tianli Group, Inc. Common Shares
ABAC
| $215K | ﹤0.01% |
102,475
+7,899
| +8% | +$16.1K |
|
|
RDGT
2986
Ridgetech Inc
RDGT
$3.19M
| $212K | ﹤0.01% |
3
-1
| -25% | -$63.4K |
|
|
TISA
2987
DELISTED
TOP Image Systems Ltd
TISA
| $211K | ﹤0.01% |
167,300
+2,700
| +2% | +$3.46K |
|
2988
Atkore
ATKR
$3.17B
| $210K | ﹤0.01% |
9,300
-307,000
| -97% | -$7.23M |
|
|
IVTY
2989
DELISTED
Invuity, Inc
IVTY
| $210K | ﹤0.01% |
28,900
+9,900
| +52% | +$76.9K |
|
2990
Sunrun
RUN
$2.37B
| $209K | ﹤0.01% |
+29,300
| New | +$158K |
|
|
TAHO
2991
DELISTED
Tahoe Resources Inc
TAHO
| $209K | ﹤0.01% |
+24,200
| New | +$211K |
|
2992
Tantech Holdings
TANH
$5.27M
| $207K | ﹤0.01% |
9
-2
| -18% | -$38.9K |
|
|
DGSE
2993
DELISTED
DGSE Companies, Inc.
DGSE
| $206K | ﹤0.01% |
123,600
+63,300
| +105% | +$103K |
|
|
ATYR
2994
aTyr Pharma
ATYR
$54.2M
| $205K | ﹤0.01% |
4,307
+1,536
| +55% | +$71.9K |
|
2995
Fortress Biotech
FBIO
$99M
| $203K | ﹤0.01% |
+2,847
| New | +$168K |
|
2996
Cerus
CERS
$572M
| $201K | ﹤0.01% |
80,100
-12,400
| -13% | -$39.7K |
|
|
FMSA
2997
DELISTED
Fairmount Santrol Holdings Inc.
FMSA
| $201K | ﹤0.01% |
+51,469
| New | +$267K |
|
|
PACD
2998
DELISTED
Pacific Drilling S A
PACD
| $201K | ﹤0.01% |
117,290
+15,500
| +15% | +$28.4K |
|
|
AHPI
2999
DELISTED
Allied Healthcare Products
AHPI
| $198K | ﹤0.01% |
68,650
+6,700
| +11% | +$13.8K |
|
3000
Oramed Pharmaceuticals
ORMP
$182M
| $195K | ﹤0.01% |
+25,100
| New | +$189K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.